Axsome reports Phase 3 depression fail for Sunosi
Axsome Therapeutics said Tuesday that a Phase 3 trial for its narcolepsy drug Sunosi failed to meet its primary goal in major depressive disorder. The company was testing Sunosi in patients who had MDD with ...
Axsome Therapeutics said Tuesday that a Phase 3 trial for its narcolepsy drug Sunosi failed to meet its primary goal in major depressive disorder.
The company was testing Sunosi in patients who had MDD with ...
